Bromantane: A Literature Course in Six Modules

Bromantane is not a peptide. It is a small synthetic organic molecule built on an adamantane cage joined to a bromophenylamine group, and it contains no amino acids and no peptide bonds. The compound appears in the pharmacology literature under two names that describe the same substance: bromantane in older and toxicology-focused papers, and ladasten in the later Russian clinical and neuropharmacology work, including a study of dopaminergic neurotransmission and hippocampal synaptic plasticity in rats (PMID 17854844) and a study of dopamine-biosynthesis gene expression in rat brain structures (PMID 15500036). This page is for educational purposes only and is not medical advice; consult a licensed physician before making any decision about any substance discussed here.

This course summarises what the published record contains, module by module, and states at the end of each module where the evidence stops. It does not reproduce dosing figures, because the verified papers used here are indexed at abstract level and the specific regimens they used cannot be represented accurately without over-reading them.

Module 1: What Bromantane Is and How It Has Been Studied

Definition and class

Bromantane belongs to the adamantane family of compounds, a chemical class better known for antiviral and antiparkinsonian agents. In the Russian literature it was grouped as an actoprotector and later as an anti-asthenic agent, meaning it was investigated for endpoints related to fatigue, performance under load and asthenic states rather than for a single receptor target. A pilot clinical trial of ladasten was published in a Russian pharmacology journal and reported on the drug in that anti-asthenic framing (PMID 16995430), while comparative rodent work placed it alongside the psychostimulant sydnocarb and examined how far dopaminergic and serotonergic systems accounted for its psychopharmacological effects (PMID 20369592).

Origin and forms

The compound originated in Soviet and Russian pharmacology programmes, which is why almost the entire primary literature is Russian-language and indexed in journals such as Eksperimental'naia i klinicheskaia farmakologiia, the Bulletin of Experimental Biology and Medicine and Voenno-meditsinskii zhurnal, where neuro- and psychophysiological effects of bromantane were described (PMID 10998997). The form described in the clinical work is an orally administered pharmaceutical preparation. Outside that setting, material labelled bromantane circulates as a research chemical powder or capsule. There is no peptide form, no injectable pharmaceutical form described in this literature set, and no reason from chemistry to expect the compound to behave like a peptide.

Limits of the evidence in Module 1

The identity and classification of bromantane are clear, but the classification terms themselves are not standard international pharmacological categories. Most primary reports are Russian-language, several are indexed only by abstract, and the verified set contains no systematic review, no meta-analysis and no independent multi-centre replication. Readers should treat "actoprotector" and "anti-asthenic" as historical descriptors of research intent, not as validated indications.

Module 2: Mechanism as Described in the Literature

Dopamine synthesis and release

The mechanistic work concentrates on dopamine. One rat study reported that ladasten induced the expression of genes regulating dopamine biosynthesis in several brain structures, an upstream mechanism distinct from simple receptor agonism (PMID 15500036). A separate rat study examined dopaminergic neurotransmission together with hippocampal synaptic plasticity and reported that ladasten affected both dopaminergic transmission measures and plasticity endpoints in the hippocampus (PMID 17854844). Taken together, researchers described a profile in which synthesis and release machinery, rather than direct stimulant-type receptor activity alone, carried the pharmacology.

Dopaminergic versus serotonergic contributions

A comparative study set ladasten against sydnocarb and asked which monoamine systems mediated the behavioural effects, reporting that both brain dopaminergic and serotonergic systems were involved in the psychopharmacological profile (PMID 20369592). This is one of the few papers in the set that attempts mechanistic dissection by comparison with a reference compound.

Immune and cytokine endpoints

A second mechanistic strand is immunological. In mice with an experimental depression-like syndrome, the study examined cytokine markers of inflammation alongside behaviour and reported changes in both domains after ladasten (PMID 22803040). A related report in an experimental model of anxious depression in C57BL/6 male mice also paired cytokine levels with behavioural measures (PMID 22288152). Lymphocyte endpoints were examined too: one paper reported effects of ladasten on proliferative activity and apoptosis in peripheral blood T-lymphocytes (PMID 12596534), and another reported a correcting effect on the subpopulation composition of T lymphocytes in C57BL/6 mice in an anxious-depressive model (PMID 24771370).

Limits of the evidence in Module 2

Every mechanistic finding above comes from rodent tissue or rodent brain. The verified set contains no human receptor-occupancy imaging, no human microdialysis and no human biomarker study confirming that the same dopamine-synthesis or cytokine changes occur in people. Mechanistic plausibility is not evidence of clinical effect, and gene-expression or cytokine shifts in a model do not establish a direction of benefit or harm for any human condition.

Module 3: Reported Outcomes by Study

The table below summarises models, endpoints and what researchers reported, without converting any of it into an expected result for any individual.

Limits of the evidence in Module 3

No study in this set is a large randomised, double-blind, placebo-controlled trial with pre-registered endpoints. The human-facing reports are a pilot trial (PMID 16995430) and a neuro-psychophysiological description (PMID 10998997), formats that generate hypotheses rather than confirm effects. Rodent depression and anxiety models do not map one-to-one onto human psychiatric diagnoses, effect sizes cannot be transferred across species, and nothing here establishes benefit in healthy people, in cognition, in athletic performance or in any specific medical condition.

Module 4: Bromantane Side Effects: What Studies Report

Safety information in the verified literature is preclinical and endpoint-specific rather than a catalogue of human adverse events.

• Neurological status after a single administration. A toxicology-oriented paper examined the toxic effect of single treatment with bromantane on the neurological status of experimental animals and reported neurological changes under those single-administration conditions (PMID 12124651).
• Neurological status after repeated administration. A separate paper examined the effect of bromantane on rat neurologic status over a two-month course and reported on neurological findings across that repeat-dosing period (PMID 11109517).
• Cardiovascular and sympathetic-adrenal endpoints. An animal study examined the effect of bromantane on the cardiovascular and sympathetic-adrenal systems and reported effects on those systems (PMID 10763107), which is the closest the set comes to a haemodynamic safety signal.
• Immune parameters. Because lymphocyte proliferation and apoptosis were reported as responsive endpoints (PMID 12596534), immune measures belong in any safety discussion rather than only in the benefit column.
• Human tolerability. Human tolerability information in this set is confined to a pilot clinical trial of ladasten (PMID 16995430), a design that is too small to characterise uncommon or delayed harms.

Limits of the evidence in Module 4

Two rodent neurological-status studies and one animal cardiovascular study do not constitute a safety database. The verified set contains no long-term human safety cohort, no pharmacovigilance analysis, no reproductive or developmental toxicology, no paediatric or geriatric data, no data in hepatic or renal impairment and no drug-interaction studies. The absence of a reported adverse event in this literature is not evidence that the event does not occur.

Module 5: Pharmacokinetics Where Data Exist

Stated plainly: the verified literature summarised on this page contains no dedicated pharmacokinetic study of bromantane or ladasten. There is no paper here reporting absorption, bioavailability, time to peak concentration, distribution volume, plasma half-life, metabolic pathway, metabolite identity, renal or hepatic clearance, or accumulation with repeated administration in either animals or humans.

What can be said indirectly is limited. The design of the two-month rat study implies that repeated administration over weeks was feasible in that model while neurological status was monitored (PMID 11109517), and the single-administration toxicology study implies that acute exposure endpoints were measurable after one treatment (PMID 12124651). Gene-expression work in rat brain regions confirms that the compound reached central nervous tissue targets sufficiently to alter transcription of dopamine-biosynthesis genes (PMID 15500036), which is an inference about central availability rather than a measured pharmacokinetic parameter.

Limits of the evidence in Module 5

Inferring exposure from study design is not pharmacokinetics. Without measured concentration-time data, the duration of action, the risk of accumulation, the influence of metabolism on inter-individual variability and the potential for interactions all remain unquantified in this set. Any number circulating elsewhere for half-life or detection window is outside what these papers support.

Module 6: Regulatory Status, Stated Factually

Bromantane's regulatory position differs sharply by jurisdiction, and the literature reflects that split: the clinical work appears as a pilot trial of a pharmaceutical preparation in a Russian journal (PMID 16995430), while the rest of the record is laboratory research (PMID 17854844).

• Approved products. Ladasten was developed and marketed as a prescription anti-asthenic medicine in Russia. That approval is jurisdiction-specific and does not extend to other countries.
• United States and European Union. There is no bromantane product approved by the US Food and Drug Administration or by the European Medicines Agency. The compound is not an approved drug substance in those jurisdictions and is not established as a lawful dietary supplement ingredient in the United States.
• Research-use-only status. Where bromantane is supplied outside Russia, it is typically offered as a research chemical labelled for laboratory use only and not for human consumption. Research-use-only labelling is a supply designation, not a safety or quality assurance, and such material is not subject to pharmaceutical manufacturing standards.
• Compounding. Under US rules, a bulk drug substance used by a compounding pharmacy generally must be a component of an FDA-approved drug, be the subject of an applicable USP or NF monograph, or appear on FDA's list of bulk drug substances that may be used in compounding. Bromantane does not fall into those categories, so it is not a substance available through lawful pharmacy compounding in the United States.
• Sport. Bromantane has been treated as a prohibited substance under anti-doping rules, so its presence in a sample can constitute an anti-doping rule violation for athletes subject to testing.

Limits of the evidence in Module 6

Regulatory status changes over time and by country, and lists are revised. Nothing in this module is legal advice; readers should confirm current status with the relevant regulator or a qualified professional in their own jurisdiction.

Closing: What the Studies Did Not Test

The verified literature on bromantane leaves large areas untouched, and naming them is part of reading it honestly:

1. Healthy human enhancement. No study here tested cognition, mood, motivation or physical performance in healthy volunteers against placebo; the human reports are a pilot trial and a neuro-psychophysiological description (PMID 16995430, PMID 10998997).
2. Comparison with established treatments. The only head-to-head comparison in the set was against another experimental stimulant in rodents (PMID 20369592), not against first-line approved therapies in patients.
3. Durability. No study followed human outcomes after discontinuation; the longest repeated-administration design here was a two-month rat neurological-status course (PMID 11109517).
4. Pharmacokinetics and interactions. Absent entirely from this set, as Module 5 describes.
5. Special populations and product quality. No pregnancy, paediatric, organ-impairment or polypharmacy data, and no analysis of the purity or identity of non-pharmaceutical material.

Read as a whole, the record describes a dopamine-synthesis-oriented small molecule with rodent behavioural, plasticity and immune findings (PMID 15500036, PMID 22803040) and early-stage human reporting (PMID 16995430). It does not describe a compound whose human risks and benefits have been characterised. This page is educational only and is not medical advice.

References

• Toxic effect of single treatment with bromantane on neurological status of experimental animals (Bulletin of Experimental Biology and Medicine, 2002)
• The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats (Neuropharmacology, 2007)
• Effect of ladasten on proliferative activity and apoptosis in peripheral blood T-lymphocytes (Eksperimental'naia i Klinicheskaia Farmakologiia, 2002)
• The effect of bromantane on the cardiovascular and sympathetic-adrenal systems in animals (Eksperimental'naia i Klinicheskaia Farmakologiia, 2000)
• Effect of ladasten on the content of cytokine markers of inflammation and behavior of mice with experimental depression-like syndrome (Bulletin of Experimental Biology and Medicine, 2011)
• Role of the brain dopaminergic and serotoninergic systems in psychopharmacological effects of ladasten and sydnocarb (Eksperimental'naia i Klinicheskaia Farmakologiia, 2010)
• The neuro- and psychophysiological effects of bromantane (Voenno-Meditsinskii Zhurnal, 2000)
• Ladasten induces the expression of genes regulating dopamine biosynthesis in various structures of rat brain (Eksperimental'naia i Klinicheskaia Farmakologiia, 2004)
• Pilot clinical trial of ladasten (Eksperimental'naia i Klinicheskaia Farmakologiia, 2006)
• Effect of bromantane on the rat neurologic status in two month course (Eksperimental'naia i Klinicheskaia Farmakologiia, 2000)
• Correcting effect of ladasten on variations in the subpopulation composition of T lymphocytes in C57BL/6 mice on the experimental model of an anxious-depressive state (Bulletin of Experimental Biology and Medicine, 2014)
• Effect of antiasthenic drug ladasten on the level of cytokines and behavior in experimental model of anxious depression in C57BL/6 male mice (Eksperimental'naia i Klinicheskaia Farmakologiia, 2011)